Epidemiology and Morbidity of Epstein-Barr Virus Infection in Pediatric Renal Transplant Recipients: A Multicenter, Prospective Study
Open Access
- 5 October 2012
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 56 (1) , 84-92
Abstract
Background. The epidemiology and morbidity of Epstein-Barr virus (EBV) infection in pediatric renal transplant recipients have been characterized insufficiently. Methods. In a prospective, multicenter study among 106 pediatric kidney allograft recipients aged 11.4 ± 5.9 years, we investigated the epidemiology of EBV infection and the relationship between EBV load, EBV serology, and EBV-related morbidity (posttransplant lymphoproliferative disease [PTLD] or symptomatic EBV infection, defined as flu-like symptoms or infectious mononucleosis). Results. EBV primary infection occurred in 27 of 43 (63%) seronegative patients and reactivation/reinfection in 28 of 63 (44%) seropositive patients. There was no association between the degree or duration of EBV load and EBV-related morbidity: The vast majority (17 of 18 [94%]) of patients with a high, persistent EBV load remained PTLD-free throughout a follow-up of 5.0 ± 1.3 years, while 2 of 3 (66%) patients with EBV-related PTLD exhibited only a low EBV load beforehand. Eight of 18 (44%) patients with a high, persistent EBV load remained asymptomatic during a follow-up of 5.3 ± 2.9 years. Multivariate analysis identified the EBV high-risk (D+/R–) serostatus (odds ratio [OR], 7.07; P < .05), the presence of human leukocyte antigen (HLA)–DR7 (OR, 5.65; P < .05), and the intensity of the immunosuppressive therapy (OR, 1.53; P < .01) as independent risk factors for the development of a symptomatic EBV infection. Conclusions. Presence of EBV high-risk seroconstellation, HLA-DR7, and intensity of immunosuppressive therapy are significant risk factors for a symptomatic EBV infection, whereas there is no close association between the degree or duration of EBV load and EBV-related morbidity. Clinical Trials Registration. NCT00963248.Keywords
This publication has 37 references indexed in Scilit:
- (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantationTransplant International, 2012
- Epstein-Barr virus load for early detection of lymphoproliferative disorder in pediatric renal transplant recipientsClinical Nephrology, 2011
- Asymptomatic high Epstein–Barr viral load carriage in pediatric renal transplant recipientsPediatric Transplantation, 2011
- B lymphocytes and Epstein–Barr virus: The lesson of post-transplant lymphoproliferative disordersAutoimmunity Reviews, 2007
- New Developments in the Diagnosis and Management of Posttransplantation Lymphoproliferative Disorders in Solid Organ Transplant RecipientsClinical Infectious Diseases, 2004
- RELATIONSHIP BETWEEN CD8+ T-CELL PHENOTYPE AND FUNCTION, EPSTEIN-BARR VIRUS LOAD, AND CLINICAL OUTCOME IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS: A PROSPECTIVE STUDY1Transplantation, 2004
- Limitations of EBV–PCR monitoring to detect EBV associated post‐transplant lymphoproliferative disorderPediatric Transplantation, 2003
- Epstein-Barr virus monitoring in paediatric renal transplant recipientsPediatric Nephrology, 2002
- Diagnosis and Management of Posttransplant Lymphoproliferative Disorder in Solid‐Organ Transplant RecipientsClinical Infectious Diseases, 2001
- Seroepidemiology of the Virus1979